期刊信息
主办:沈阳药科大学;中国药学会
主管:辽宁省教育厅
ISSN:1005-0108
CN:21-1313/R
语言:中文
周期:月刊
影响因子:0.190283
数据库收录:
文摘杂志;北大核心期刊(2017版);化学文摘(网络版);中国科学引文数据库(2011-2012);中国科学引文数据库(2013-2014);中国科学引文数据库(2015-2016);中国科学引文数据库(2017-2018);中国科学引文数据库(2019-2020);日本科学技术振兴机构数据库;中国科技核心期刊;期刊分类:药学
期刊热词:
研究论文
冠心病介入治疗术后造影剂肾病的药物防治进展(4)
【作者】网站采编
【关键词】
【摘要】[15] Ellis JH,Cohan the risk of contrast-induced nephropathy:a perspective on the controversies[J].AJR Am J Roentgenol,2009,192(6):1544-9. [16] Stacul F,van der Molen AJ,Reimer P,et induced nephropath
[15] Ellis JH,Cohan the risk of contrast-induced nephropathy:a perspective on the controversies[J].AJR Am J Roentgenol,2009,192(6):1544-9.
[16] Stacul F,van der Molen AJ,Reimer P,et induced nephropathy:updated ESUR Contrast Media Safety Committee guidelines[J].Eur Radiol,2011,21(12):2527-41.
[17] Pranata R,Tondas AE,Vania R,MPL T,Lukito AA, Siswanto ischemic preconditioning reduces the incidence of contrast-induced nephropathy in patients undergoing coronary angiography/intervention:Systematic review and meta-analysis of randomized controlled trials[M].Catheter Cardiovasc Interv,2020.
[18] Firouzi A,Alemzadeh-Ansari MJ,Mohammadhadi N,et al. Association between the risks of contrast-induced nephropathy after diagnostic or interventional coronary management and the transradial and transfemoral access approaches[J].J Cardiovasc Thorac Res,2020.12(1):51-55.
[19] Grekas D,Dioudis C,Papageorgiou G,et al.Lipid peroxidation after acute renal ischemia and reperfusion in rats:the effect of trimetazidine[J].Ren Fail,1996. 18(4):545-52.
[20] Akgüllü ?,Saruhan T,Eryilmaz U,et al.The first histopathological evidence of trimetazidine for the prevention of contrast-induced nephropathy[J].Ren Fail,2014,36(4):575-80.
[21] Onbasili AO,Yeniceriglu Y,Agaoglu P,et al. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures[J].Heart,2007,93(6):698-702.
[22] Shehata M.Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention[J].Am J Cardiol,2014.114(3):389-94.
[23] Deng J,Wu G,Yang C,Li Y,Jing Q,Han attenuates contrast-induced nephropathy through modulation of nitric oxide, inflammatory responses, oxidative stress and apoptosis in diabetic male rats[J].J Transl Med,2015(13):53.
[24] He X,Yang J,Li L,et protects against contrast-induced nephropathy via anti-apoptosis by the upregulation of Hsp27 in vivo and in vitro[J].Mol Med Rep, 2017,15(4):1963-1972.
[25] Fu N,Liang M,Yang S.High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention[J].Angiology,2018,69(8):692-699.
[26] Leoncini M,Toso A,Maioli M,Tropeano F,Villani S, Bellandi F.Early high-dose rosuvastatin for contrastinduced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome)[J].J Am Coll Cardiol,2014,63(1):71-9.
[27] Liu Y,He YT,Tan N,et N-terminal pro-brain natriuretic peptide (NT-proBNP) is similar to the Mehran contrast-induced nephropathy (CIN) score in predicting CIN following elective coronary angiography[J].J Am Heart Assoc,2015,4(4).
[28] Liu JM,Xie YN,Gao ZH,et al.Brain natriuretic peptide for prevention of contrast-induced nephropathy after percutaneous coronary intervention or coronary angiography[J].Can J Cardiol,2014,30(12):1607-12.
[29]李益民,王治,陆治平,等.重组脑利钠肽对造影剂肾病的预防作用[J].江苏医药,2017,43(02):111-113.
[30] Shimizu S,Saito M,Kinoshita Y,et ameliorates ischaemia-reperfusion injury in the rat kidney[J].Br J Pharmacol,2011,163(2):272-82.
[31] Khames A,Khalaf MM, Gad AM,Abd EOM,Kandeil MA. Nicorandil combats doxorubicin-induced nephrotoxicity via amendment of TLR4/P38 MAPK/NFκ-B signaling pathway[J]. Chem Biol Interact,2019.311:.
[32] Fan Z,Li Y,Ji H,Jian of Oral Nicorandil to Prevent Contrast-Induced Nephropathy in Patients with Chronic Renal Dysfunction Undergoing an Elective Coronary Procedure[J].Kidney Blood Press Res,2019,44(6):1372-1382.
[33] Pranata R,Vania R,Alkatiri AA,Firman D,Lukito reduces the incidence of contrastinduced nephropathy in patients undergoing coronary angiography/intervention-Systematic review and metaanalysis of randomized controlled trials including GRADE qualification[M].Cardiovasc Revasc Med,2020.
文章来源:《中国药物化学杂志》 网址: http://www.zgywhxzz.cn/qikandaodu/2021/0622/590.html
上一篇:几种药物抗弓形虫活性的检测
下一篇:打印药物复合材料在生物医学中的应用